Amgen completed the acquisition of Dark Blue Therapeutics for $840m.

Amgen, an independent biotechnology medicines company, completed the acquisition of Dark Blue Therapeutics, a company focused on developing transformational medicines for cancer patients, for $840m. "Acute myeloid leukemia remains one of the most difficult cancers to treat, and we see an urgent need for new mechanisms capable of changing the trajectory of this disease. This acquisition complements and extends our research in targeted protein degradation and leukemia therapeutics, advancing our strategy to invest early in rising medicines for novel therapeutic targets. The adjacency of this program to our considered expertise in cancer biology will propel MLLT1/3-targeting medicines to clinical investigation for patients facing the challenging diagnosis of AML," Jay Bradner, Amgen Executive Vice President of Research and Development.